← back to search

Scott V. Bratman

Council of Ontario Universities · CA
Area of research
Otorhinolaryngology · Cancer Research
Research interest
Research interests include Head and Neck Cancer Studies, Cancer Genomics and Diagnostics, Radiomics and Machine Learning in Medical Imaging, and Cancer Immunotherapy and Biomarkers.
h-index
53
citations
16,933
works
634
NIH funding
primary concept
email

Recent publications

Investigating Early Kinetics in Plasma ctDNA and Peripheral T-cell Receptor Repertoire to Predict Treatment Outcomes to PD-1 Inhibitors in Head and Neck Squamous Cell Carcinoma.
2026cited by 0position: contributordoi
Exploring the Utility of Cell-Free DNA Hydroxymethylation Profiling in Small-Cell Lung Cancer
International Journal of Molecular Sciences 2026cited by 0position: contributordoi
Data from Investigating Early Kinetics in Plasma ctDNA and Peripheral T-cell Receptor Repertoire to Predict Treatment Outcomes to PD-1 Inhibitors in Head and Neck Squamous Cell Carcinoma
2026cited by 0position: contributordoi
Supplementary Figures 1 from Investigating Early Kinetics in Plasma ctDNA and Peripheral T-cell Receptor Repertoire to Predict Treatment Outcomes to PD-1 Inhibitors in Head and Neck Squamous Cell Carcinoma
2026cited by 0position: contributordoi
Supplementary Tables 1 from Investigating Early Kinetics in Plasma ctDNA and Peripheral T-cell Receptor Repertoire to Predict Treatment Outcomes to PD-1 Inhibitors in Head and Neck Squamous Cell Carcinoma
2026cited by 0position: contributordoi
Ultrasensitive Detection and Monitoring of Circulating Tumor DNA Using Structural Variants in Early-Stage Breast Cancer.
2025cited by 16position: contributordoi
Association between Locoregional Failure and NFE2L2/KEAP1/CUL3 Mutations in NRG/RTOG 9512: A Randomized Trial of Radiation Fractionation in T2N0 Glottic Cancer.
2025cited by 6position: contributordoi
Circulating human papillomavirus DNA sequencing as a biomarker of response in advanced cervical cancer
International Journal of Gynecological Cancer 2025cited by 4position: contributordoi
Cross-ancestral GWAS identifies 29 variants across head and neck cancer subsites
Nature Communications 2025cited by 3position: middledoi
Adaptive Universal Principles for Real-world Observational Studies (AUPROS): an approach to designing real-world observational studies for clinical, epidemiologic, and precision oncology research.
2025cited by 2position: contributordoi
Data from Ultrasensitive Detection and Monitoring of Circulating Tumor DNA Using Structural Variants in Early-Stage Breast Cancer
2025cited by 1position: contributordoi
Supplementary Data 1 from Ultrasensitive Detection and Monitoring of Circulating Tumor DNA Using Structural Variants in Early-Stage Breast Cancer
2025cited by 1position: contributordoi
Positron Emission Tomography/Computed Tomography (PET/CT) and Radioimmunotherapy of Head and Neck Cancer Patient Derived Xenografts in NRG Mice with Theranostic [<sup>64</sup>Cu]Cu-DOTA-Panitumumab F(ab')<sub>2</sub> and [<sup>177</sup>Lu]Lu-DOTA-Panitumumab F(ab')<sub>2</sub>.
2025cited by 0position: contributordoi
Supplementary Table 1 from Ultrasensitive Detection and Monitoring of Circulating Tumor DNA Using Structural Variants in Early-Stage Breast Cancer
2025cited by 0position: contributordoi
Supplementary Table S1 from Association between Locoregional Failure and <i>NFE2L2/KEAP1/CUL3</i> Mutations in NRG/RTOG 9512: A Randomized Trial of Radiation Fractionation in T2N0 Glottic Cancer
2025cited by 0position: contributordoi
Supplementary Figure 3 from Ultrasensitive Detection and Monitoring of Circulating Tumor DNA Using Structural Variants in Early-Stage Breast Cancer
2025cited by 0position: contributordoi
Supplementary Table S8 from Association between Locoregional Failure and <i>NFE2L2/KEAP1/CUL3</i> Mutations in NRG/RTOG 9512: A Randomized Trial of Radiation Fractionation in T2N0 Glottic Cancer
2025cited by 0position: contributordoi
Supplementary Table S3 from Association between Locoregional Failure and <i>NFE2L2/KEAP1/CUL3</i> Mutations in NRG/RTOG 9512: A Randomized Trial of Radiation Fractionation in T2N0 Glottic Cancer
2025cited by 0position: contributordoi
Outcomes and characteristics of patients receiving pre-operative versus post-operative radiotherapy for sinonasal squamous cell carcinoma.
2025cited by 0position: contributordoi
Supplementary Table 6 from Ultrasensitive Detection and Monitoring of Circulating Tumor DNA Using Structural Variants in Early-Stage Breast Cancer
2025cited by 0position: contributordoi
Supplementary Table S5 from Association between Locoregional Failure and <i>NFE2L2/KEAP1/CUL3</i> Mutations in NRG/RTOG 9512: A Randomized Trial of Radiation Fractionation in T2N0 Glottic Cancer
2025cited by 0position: contributordoi
Supplementary Table S2 from Association between Locoregional Failure and <i>NFE2L2/KEAP1/CUL3</i> Mutations in NRG/RTOG 9512: A Randomized Trial of Radiation Fractionation in T2N0 Glottic Cancer
2025cited by 0position: contributordoi
Supplementary Table S6 from Association between Locoregional Failure and <i>NFE2L2/KEAP1/CUL3</i> Mutations in NRG/RTOG 9512: A Randomized Trial of Radiation Fractionation in T2N0 Glottic Cancer
2025cited by 0position: contributordoi
Supplementary Table 5 from Ultrasensitive Detection and Monitoring of Circulating Tumor DNA Using Structural Variants in Early-Stage Breast Cancer
2025cited by 0position: contributordoi
Supplementary Figure 1 from Ultrasensitive Detection and Monitoring of Circulating Tumor DNA Using Structural Variants in Early-Stage Breast Cancer
2025cited by 0position: contributordoi
Supplementary Figure S2 from Association between Locoregional Failure and <i>NFE2L2/KEAP1/CUL3</i> Mutations in NRG/RTOG 9512: A Randomized Trial of Radiation Fractionation in T2N0 Glottic Cancer
2025cited by 0position: contributordoi
Supplementary Table S7 from Association between Locoregional Failure and <i>NFE2L2/KEAP1/CUL3</i> Mutations in NRG/RTOG 9512: A Randomized Trial of Radiation Fractionation in T2N0 Glottic Cancer
2025cited by 0position: contributordoi
Supplementary Table 3 from Ultrasensitive Detection and Monitoring of Circulating Tumor DNA Using Structural Variants in Early-Stage Breast Cancer
2025cited by 0position: contributordoi
Supplementary Table 7 from Ultrasensitive Detection and Monitoring of Circulating Tumor DNA Using Structural Variants in Early-Stage Breast Cancer
2025cited by 0position: contributordoi
Data from Association between Locoregional Failure and <i>NFE2L2/KEAP1/CUL3</i> Mutations in NRG/RTOG 9512: A Randomized Trial of Radiation Fractionation in T2N0 Glottic Cancer
2025cited by 0position: contributordoi

Grants

No grants ingested yet.

Frequent collaborators

· 188 papers (2019–2026)Lillian L. Siu · Princess Margaret Cancer Centre93 papers (2020–2026)Shao Hui Huang · University of Toronto73 papers (2019–2025)Trevor Pugh · University of Pennsylvania70 papers (2019–2026) · 63 papers (2019–2025)Fei-Fei Liu · Jiangsu Hengrui Medicine (China)62 papers (2019–2023)Benjamin Haibe‐Kains · Structural Genomics Consortium51 papers (2019–2023)Aaron R. Hansen · Cancer Council Queensland50 papers (2019–2026) · 50 papers (2019–2023)Enrique Sanz-Garcia · Vall d'Hebron Institute of Oncology42 papers (2022–2026)Pamela S. Ohashi · Discovery Centre42 papers (2024–2026)Anna Spreafico · Princess Margaret Hospital41 papers (2024–2026)Justin Burgener · Foster-Miller (United States)40 papers (2019–2024)Philippe L. Bedard · Vall d'Hebron Institute of Oncology40 papers (2020–2024)Eric Y. Zhao · MacroGenics (United States)39 papers (2020–2024) · 39 papers (2024–2024)Stéphanie Lheureux · Princess Margaret Cancer Centre39 papers (2024–2024)Albiruni Abdul Razak · University of Toronto38 papers (2024–2024)P. Awadalla · Saskatchewan Health38 papers (2022–2024)Yong Zeng · Second Xiangya Hospital of Central South University37 papers (2024–2024)